Background. The bleeding impact of dual antiplatelet therapy (DAPT), aspirin and clopidogrel, maintained until coronary artery bypass graft surgery (CABG), is still a matter of debate. The lack of preoperative antiplatelet activity measurement and heterogeneity of antifibrinolytic protocols in prior studies make the conclusions questionable. The aim of this prospective study was to determine, after preoperative antiplatelet activity measurement, if the maintenance of DAPT until CABG increases bleeding in patients treated with tranexamic acid (TA). Methods. This observational study included 150 consecutive patients, 89 treated with aspirin and 61 treated with DAPT, undergoing a first-time planned on-pump CABG with TA treatment. Antiplatelet activity was measured with platelet aggregation tests and quantification of VASP phosphorylation. Postoperative bleeding at 24 h was recorded and propensity score analysis was performed. Results. Based on VASP assay, 54% of patients showed high on-clopidogrel platelet activity inhibition. Postoperative bleeding at 24 h increased by 22% in the DAPT group, compared with the aspirin group (680 [95% CI: 360-1670] vs 558 [95%CI: 267-1270] ml, P < 0.01), consistent with increased blood transfusion (21% vs 7%, P ¼ 0.01); a higher incidence of mediastinitis did not reach statistical significance (15% vs 4%, P ¼ 0.05). Bleeding correlated with the extent of clopidogrel antiplatelet effect, with the best correlation for the VASP assay. Conclusions. Maintenance of DAPT until the day of CABG in patients treated with TA, increased postoperative bleeding at 24 h in parallel with preoperative antiplatelet activity induced by clopidogrel.
The benefit of dual antiplatelet therapy (DAPT), such as clopidogrel combined with aspirin, is well-established in the treatment of both acute coronary syndrome and ischaemic cardiomyopathy. 1 Aspirin maintenance during surgery does not increase the postoperative bleeding in coronary artery bypass grafting (CABG) patients, 2 but continuation of DAPT until CABG is a matter of debate. Several studies and meta-analyses have tried to address this question, 1 3-6 and guidelines have been published. [6] [7] [8] Nevertheless, conclusions are questionable because of major methodological concerns. The most important bias is lack of preoperative platelet activity measurement, even though a large inter-individual variability in response to clopidogrel is well known. [9] [10] [11] In one retrospective study that assessed platelet activity, patients undergoing off-pump or onpump CABG 9 were combined, even though cardio-pulmonary bypass (CPB) is known to impact postoperative bleeding. 12 While intraoperative treatment with anti-fibrinolytic agents can reduce perioperative bleeding in cardiac surgery, 13 14 in most studies neither antifibrinolytic agents nor standardized infusion protocols were used, increasing study heterogeneity. 9 15 16 With aprotinin, postoperative bleeding was not increased when DAPT was maintained until the day of surgery. 14 Since withdrawal of aprotinin from the market, tranexamic acid (TA) is currently recommended in cardiac surgery despite being less efficacious. 7 In addition, TA might partially reverse the effect of platelet activity inhibition by DAPT. 17 The present study was designed to compare postoperative bleeding at 24 h after maintenance of DAPT vs aspirin alone, in patients undergoing on-pump elective primary CABG and receiving TA infusion. Systematic preoperative platelet activity measurements were performed in each patient to distinguish clopidogrel good-responders and poor-responders.
Methods

Patients
The ICARE study (ClinicalTrial.gov: NCT01216150) is a prospective observational trial conducted at a large academic hospital from December 2009 to November 2010, when maintenance of DAPT until the day of surgery was usual in our institution. We performed an observational study to assess impact of DAPT on postoperative bleeding by propensity score analysis using boosted regression trees. No additional blood sample was required for this study, and measurements performed are routine for all patients undergoing cardiac surgery. As preoperative antiplatelet activity was measured in residual blood samples (<5 ml), waived informed consent was approved by the ethical committee. However, verbal and written information was given to patients.
During the study period, all patients undergoing elective isolated first-time CABG were enrolled. 14 We excluded patients in whom mechanical support or intra-aortic balloon pump was required, as their antithrombotic therapy management differs during the postoperative period. We also excluded all patients who did not receive aspirin until surgery, those who had been preoperatively exposed to antiplatelet glycoprotein IIb/IIIa inhibitors, and those with a history of haematological disease that can interfere with coagulation or platelet functions.
Patients treated with DAPT and in whom clopidogrel was stopped > 10 days before surgery were included in the aspirin group. In case of clopidogrel discontinuation < 10 days before surgery, patients were excluded to rule out a potential residual effect of clopidogrel. Low molecular weight heparin (LMWH) was systematically discontinued 12 h before surgery.
Intraoperative management
Patients enrolled in this study were pre-treated with TA (ExacylV R , Sanofi-Aventis, Paris, France) i.v. bolus and infusion at 10 mg kg À1 for 20 min after induction of anaesthesia, followed by continuous i.v. infusion of 2 mg kg À1 h À1 until the end of surgery, according a standardized protocol. 18 In case of renal dysfunction, continuous infusion was adapted as follows:
. As described, 14 before aortic cannulation, an initial loading dose of heparin was directly administrated by the surgeon into the right atrium, to obtain a whole-blood-activated clotting time > 400 sec measured using a micro-coagulation analyzer (HemochronJr II, Inter-national Technidyne Corporation, Edison, NJ). After discontinuation of cardiopulmonary bypass, heparin was neutralized by protamine sulfate (0.008-0.01 mg IU À1 of total heparin dose). Intraoperative cell salvage was used systematically (Electa, Dideco, Mirandola, Italy).
Postoperative anti-thrombotic therapy
Early postoperative antithrombotic therapy consisted of an i.v. bolus of 100 mg aspirin given 6 h after the arrival in the intensive care unit (ICU). 14 Initial prophylactic anticoagulation was started 6 h after the end of the surgical procedure, with unfractioned heparin continuously infused at 100 IU kg À1 day À1 , switched to once daily administration of enoxaparin 40 mg the day after surgery. Transfusion was a decision left to the clinical team, and written guidelines are used in our department. In case of persistent bleeding only, platelet transfusion was administered without any blood clot formation in operating room and/or when platelet count was < 80,000 ml
À1
. No preventive transfusion was given. Based on recommendations of the Society of Thoracic Surgeons and the Society of Cardiovascular Anaesthesiologists, 19 red blood cell transfusion was recommended in our institution in case of haemoglobin < 7 g dl À1 , fresh frozen plasma transfusion in case of serious bleeding with prothrombin time less than 50%, and fibrinogen for plasma concentration less than 2 g dl
.
Preoperative platelet reactivity assessment
Preoperative platelet function inhibition was measured in each patient. Platelet aggregation tests and flow cytometric assays with vasodilator-stimulated phosphoprotein (VASP) were performed. 20 21 Aggregation studies were performed within 3 h of blood collection; test results were known retrospectively at the Editor's key points
• The impact of dual antiplatelet therapy (DAPT) on bleeding after cardiac surgery in patients treated with antifibrinolytic drugs is unclear.
• Preoperative platelet function and bleeding in the first 24 h after cardiac surgery was determined in a prospective observational study of 150 consecutive patients in a single centre.
• Bleeding was somewhat greater in patients receiving tranexamic acid and treated preoperatively with DAPT compared with aspirin alone, which correlated with degree of preoperative antiplatelet effect.
end of the study. 20 Platelet aggregation testing was performed in citrated platelet-rich plasma adjusted to 250x10 9 , Biopool, Sweden) to explore clopidogrel effect. We recorded maximal platelet aggregation (MPA) and residual platelet aggregation after 6 min (RPA). Laboratory ADP-induced MPA cut-off for distinguishing between clopidogrel good-and poorresponders was 50%. 20 To determine VASP phosphorylation state, we used a standardized flow cytometric assay (Becton Dickinson, Le Pont de Claix, France). Platelet reactivity index (PRI, %) was calculated from median fluorescence intensity.
Patients were considered as clopidogrel poor-responders to clopidogrel 75 mg-maintenance dose when PRI was > 60%. 20 22 23 The laboratory arachidonic acid-induced MPA cut-off for poorresponders to aspirin was MPA > 20%. 24 Platelet secretion was tested by their capacity to expose surface P-selectin (CD62P), after activation with thrombin receptor peptide agonist (TRAP).
21
Endpoints
The primary endpoint was chest tube blood output during the first 24 h postoperatively. For sample size calculation, we estimated 400 [200] ml (mean [SD] ) postoperative bleeding at 24 h after CABG with aspirin. 14 Excessive bleeding was defined by an increment of at least 25% of this value. 14 Secondary endpoints were rate of surgical re-exploration for excessive bleeding, transfusion requirement, prolonged postoperative mechanical ventilation (>10 h), and prolonged ICU length of stay (>72 h), overall hospital length of stay, hospital free days at 30 days, defined as number of days spent out of the hospital during the first 30 postoperative days, mediastinitis (surgical-site infection with positive bacteriological culture), and 30-day mortality defined as number of patients who died during the first 30 postoperative days.
Statistical analysis
Assuming an alpha risk of 0.05 and a beta risk of 0.20 and because mean amount of postoperative bleeding after CABG has been previously measured at 400 [200] ml in the aspirin group, 14 and as 60% of patients were treated with aspirin and 40% were treated with DAPT, we estimated that at least 134 patients should be included, 80 in the aspirin group and 54 in the DAPT group. Allowing for patients lost to follow up and technical problems in platelet function analysis, the final sample was estimated at 150 patients over 40 weeks. Data are expressed as mean (SD) or median (95% confidence interval) in non -normally distributed variables or number (%).
Comparison between groups was performed using the Student's t-test or analysis of variance and the Newman-Keuls post-hoc test in normally distributed variables, and the Mann-Whitney U-test for multiple comparisons and the Kruskal-Wallis test in non-normally distributed variables. Comparisons of proportions were performed using the Fisher exact method. Correlation between a predictor variable and a response variable was studied with linear regression analysis.
The effect of DAPT on postoperative bleeding at 24 h was assessed by propensity scores using boosted regression trees. 25 (Le Manach et al.) Patients were assigned to a propensity score that reflects the probability that they would receive DAPT. Standardized differences were used to assess the balance between groups. An absolute standardized difference (ASD) > 20% was considered to represent meaningful imbalance. As a result of the exploratory nature of the study, we made no adjustment for multiple testing. All P values are two-tailed, and P< 0.05 was considered statistically significant. Statistical analysis was performed with R (version 2.10.0, The R Foundation for Statistical Computing, http://www.r-project.org/foundation/).
Results
We included 89 (59%) patients in the aspirin group and 61 (41%) patients in the DAPT group (Fig. 1) . After propensity scorematched analysis, preoperative clinical variables did not show significant differences between groups, except for a lower prevalence of hypertension and prior non-STEMI in the aspirin group them in the DAPT group (Table 1) , while patients treated with beta-blockers and nitrate were significantly more frequent in the aspirin group than in the DAPT group (Table 1) . No patient was treated with LMWH during the 12 h before surgery. Preoperative laboratory characteristics were similar between groups; specifically, platelet count, haemoglobin and fibrinogen concentration were not significantly different between groups (data not shown).
In arachidonic acid-induced platelet aggregation testing, 11 (12%) patients in the aspirin group and 2 (3%) patients in the DAPT group were classified as poor-responders to aspirin ( Fig. 2A) . By VASP assay, the most specific test to monitor P2Y 12 inhibition, 28 patients (46%) were considered as clopidogrel poor-responders (Fig. 2C) . The MPA ADP 10 mM assay significantly differed between groups (Fig. 2B) (Table 2 ). Collagen and TRAP-induced aggregation significantly differed between groups, reflecting a higher efficiency of platelet inhibition with DAPT compared with aspirin (Table 2 ). This effect was observed for both MPA and RPA for collagen and for RPA for TRAP, reflecting a lower stability of the platelet aggregates. After activation with TRAP, P-selectin expression was lower in the DAPT than in the aspirin group (48 [95% CI: 20-86] vs 62 [95% CI: 32-107], P < 0.01).
Intraoperative period
There was no difference between aspirin and DAPT groups in use of both left and right mammary artery graft in 96% and 95%, respectively, and left mammary artery graft alone was used in 4% and 5%, respectively. Venous graft was used in association with left mammary artery graft in only 3% and 2%, respectively. Whereas the initial bolus of heparin was similar between groups, total dose of heparin required for maintaining ACT > 400 s was higher in the aspirin group (Table 3) . After heparin inhibition, both total dose of administered protamine sulfate and final ACT were similar between groups. No significant difference was noted in bypass time and cross-clamping time (Table 3) .
Volume of blood collected in the cell saver and retransfused at the end of surgery was not significantly different between Bleeding with aspirin and clopidogrel in cardiac surgery | 751 at McMaster University Library on January 2, 2017 http://bja.oxfordjournals.org/ groups (Table 3) . Intraoperative transfusion of platelet units (apheresis or random donor units) was significantly more frequent in DAPT group compared with the aspirin group (Table 4) . Using VASP assay as reference, intraoperative transfusion of platelet units was not significantly different between clopidogrel good-and poor-responders (30% vs 25%, P ¼ 0.71). RBC transfusion was not significantly different between groups. No patient was treated with LMWH during the 12 h before surgery or GPIIb/IIIa inhibitors, and preoperative medications were similar between groups (data not shown).
Postoperative period and primary outcome
At 12 h after surgery, median chest tube output was 40% higher in the DAPT group than in the aspirin group (450 [95% CI: 165-1300] ml vs 320 [95% CI: 130-890] ml, P < 0.01). Accordingly, haemoglobin concentration was significantly lower in the DAPT group compared with the aspirin group. Using the VASP test as reference, median chest tube output was significantly increased in the clopidogrel good-responder group compared with the aspirin group (510 [95% CI: 266-1400] ml vs 320 [95% CI: 130-890] ml, respectively, P < 0.01), and did not significantly differ between the clopidogrel poor-responder and aspirin groups (353 [95% CI: 155-1140] ml vs 320 [95% CI: 130-890] ml, NS).
At 24 h after surgery, median cumulative chest tube output was 22% higher in DAPT group than in the aspirin group (680 [95% CI: 360-1660] vs 558 [95% CI: 267-1270] ml, P < 0.01). Using the VASP test, median chest tube output at 24 h increased significantly both in the clopidogrel good-responder and poorresponder groups compared with the aspirin group (800 [95% CI: 437-1800] ml and 550 [95% CI: 340-1530] ml vs 558 [95% CI: 267-1270] respectively, P < 0.01). In addition, median chest tube output increased significantly in clopidogrel good-responder compared with clopidogrel poor-responder patients (P < 0.01). Whereas haemoglobin concentration was not significantly different between groups, postoperative RBC unit transfusion was significantly increased in the DAPT group compared with the aspirin group (Table 4) .
Despite a relatively low correlation between preoperative antiplatelet reactivity (platelet aggregation and VASP) and cumulative postoperative bleeding at 24 h, VASP assay was correlated best between platelet reactivity and bleeding (Fig. 3) .
In parallel with the increased transfusion, there was an increase in the incidence of postoperative mediastinitis in the DAPT group that did not reach statistical significance (4% vs 15% respectively, P ¼ 0.05). We did not find any significant difference between groups in term of prolonged mechanical ventilation (>10 h), cumulative postoperative ICU length of stay, total 421 CABG surgeries 116 combine surgeries 105 CABG + valvular surgery 9 CABG + aortic surgery 2 CABG + cardiac assistance device 16 clopidogrel stops less than 10 days before surgey 9 aspirin stops less than 10 days before surgery 9 included in an another protocol interferring with haemostasis 8 clopidogrel treatments without aspirin 6 antiplatelet therapies beginning less than 10 days before surgery (Table 4) .
Discussion
In this prospective observational study, we found that the magnitude of postoperative bleeding was greater in clopidogrel good-responders than in clopidogrel poor-responders by the VASP assay. In contrast to results obtained with aprotinin, 14 DAPT maintained until the day of surgery increased postoperative bleeding in CABG patients treated with TA. DAPT causes synergistic inhibition of thromboxane A 2 and ADP-dependent platelet activation pathways. If greater platelet inhibition until the day of the surgery increases perioperative bleeding, blood transfusion requirement and/or re-operation rate, withdrawal of clopidogrel has shown to be deleterious. 26 Several studies and meta-analyses have investigated the impact of DAPT on postoperative bleeding when clopidogrel was stopped five days before the surgery. 1 4-7 However, this was inconclusive mainly because of methodological biases such as inhomogeneous discontinuation of clopidogrel within five days before surgery, 27 heterogeneity in type of surgery such as elective or urgent, 16 27 28 on-pump or off-pump, 9 15 16 27 29 complex or redo. 16 All patients were mixed in the same study group, although these parameters are known to have different effects on postoperative bleeding. 12 Collectively, two major biases have to be considered. First, and probably most importantly, none of these studies measured preoperative platelet activity inhibition. Indeed, clopidogrel treatment results in a wide variability of inhibition of platelet function. 10 In our study, antiplatelet treatment was maintained until the day of surgery, no patient was treated with un-fractionated heparin or GPIIb/IIIa inhibitors, all patients underwent planned and first-time on-pump CABG surgery, and on-clopidogrel antiplatelet activity was systematically measured preoperatively with the VASP assay. In agreement with the literature, 9-11 30 we found 46% of clopidogrel poorresponder patients. The magnitude of postoperative bleeding increased with inhibitory response to clopidogrel, as shown with the increased bleeding between aspirin group and the clopidogrel poor-responder and clopidogrel good-responder groups, respectively. These results highlight the risk of wrong conclusions in previous meta-analysis 1 5 6 and guidelines 7 8 in part because of the lack of platelet function measurement.
A second major bias is the large heterogeneity or the lack of intraoperative antifibrinolytic pre-treatment for patients from the same groups and trials. 15 16 27 29 Antifibrinolytic agents have some differences mechanism of action. Aprotinin, a serine protease inhibitor, neutralizes free plasmin, which reduces the clot lysis. In addition to its antifibrinolytic effect, TA can have a partial reversal effect of platelet aggregation dysfunction because of DAPT. 17 A large meta-analysis including 1620 patients had showed the crucial role played by antifibrinolytic treatment in decreasing postoperative bleeding in cardiac surgery. 13 Previously, we investigated the impact of aprotinin treatment infused during the intraoperative period on postoperative bleeding, with aspirin compared with DAPT maintained until the day of CABG surgery, and concluded that postoperative bleeding at 24 h was not different between groups. 14 In the present study involving TA, an antifibrinolytic known to be less efficient than aprotinin 31 irrespective of previous DAPT exposure, postoperative bleeding at 24 h increased by 22% in the DAPT group compared with the aspirin group, especially in the clopidogrel good-responder patients. During the intraoperative period, RBC transfusion was similar between groups while platelet transfusion was greater in the DAPT group. Intraoperative platelet transfusion was recommended when platelet count was < 80,000 ml À1 and/or in case of persistent bleeding without any blood clot. The restrictive guidelines for RBC transfusion, recommended when haemoglobin was <7 g dl À1 , could explain this delayed increase in RBC transfusion.
At 24 h, haemoglobin is stable and similar between groups, maintained by RBC and platelet transfusions in the DAPT group. Unfortunately, the increase in blood transfusion requirement is known to be correlated with a greater incidence of mediastinitis. 32 Although the difference was not statistically significant, perhaps because of low power (P ¼ 0.05), we found a 4-fold (375%) increase in the incidence of mediastinitis in the DAPT group compared with aspirin group. Some limitations have to be taken into account in relation to this study. Although conducted prospectively, this was an observational study. Hidden biases cannot be completely ruled out, although the propensity score adjustment technique used in this study limited this possibility. The sample size of this study might not have been large enough to control for the complex interaction of confounders that can occur in this clinical setting. However, recognized predictors of bleeding were balanced after propensity score analysis. In addition, platelet and In conclusion, in contrast to results obtained in a previous study with aprotinin, the use of TA was associated with increased postoperative bleeding, which is all the more important given that platelet activity is consistently inhibited by clopidogrel. The consequences are increased RBC transfusion and possibly increased mediastinitis in the DAPT group compared with the aspirin group. Our findings illustrate the requirement to take into account both inter-individual response to clopidogrel and type of antifibrinolytic agent used during cardiac surgery when developing guidelines in this area.
